JP2020143156A - 心血管リスクを低減させる方法 - Google Patents

心血管リスクを低減させる方法 Download PDF

Info

Publication number
JP2020143156A
JP2020143156A JP2020097344A JP2020097344A JP2020143156A JP 2020143156 A JP2020143156 A JP 2020143156A JP 2020097344 A JP2020097344 A JP 2020097344A JP 2020097344 A JP2020097344 A JP 2020097344A JP 2020143156 A JP2020143156 A JP 2020143156A
Authority
JP
Japan
Prior art keywords
pcsk9
antibody
antigen
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020097344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020143156A5 (enExample
Inventor
ロランス・ベサック
Bessac Laurence
コリンヌ・アノトン
Hanotin Corinne
ロバート・シー・ポーディー
C Pordy Robert
ウィリアム・ジェイ・サシーラ
J Sasiela William
グレゴリー・ジー・シュウォルツ
Gregory G Schwartz
フィリップ・ガブリエル・シュテグ
Gabriel Steg Philippe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of JP2020143156A publication Critical patent/JP2020143156A/ja
Publication of JP2020143156A5 publication Critical patent/JP2020143156A5/ja
Priority to JP2022116854A priority Critical patent/JP2022141868A/ja
Priority to JP2024115429A priority patent/JP2024147744A/ja
Pending legal-status Critical Current

Links

Images

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020097344A 2014-03-17 2020-06-04 心血管リスクを低減させる方法 Pending JP2020143156A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022116854A JP2022141868A (ja) 2014-03-17 2022-07-22 心血管リスクを低減させる方法
JP2024115429A JP2024147744A (ja) 2014-03-17 2024-07-19 心血管リスクを低減させる方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US61/954,094 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US62/025,400 2014-07-16
US201462043182P 2014-08-28 2014-08-28
US62/043,182 2014-08-28
EP15305293.1 2015-02-26
EP15305293 2015-02-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016556709A Division JP2017509624A (ja) 2014-03-17 2015-03-13 心血管リスクを低減させる方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022116854A Division JP2022141868A (ja) 2014-03-17 2022-07-22 心血管リスクを低減させる方法

Publications (2)

Publication Number Publication Date
JP2020143156A true JP2020143156A (ja) 2020-09-10
JP2020143156A5 JP2020143156A5 (enExample) 2021-05-20

Family

ID=66624745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020097344A Pending JP2020143156A (ja) 2014-03-17 2020-06-04 心血管リスクを低減させる方法

Country Status (2)

Country Link
JP (1) JP2020143156A (enExample)
IL (1) IL247837A0 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220120089A (ko) * 2021-02-23 2022-08-30 연세대학교 산학협력단 하지 절단 수술의 치료 반응성을 예측하는 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220120089A (ko) * 2021-02-23 2022-08-30 연세대학교 산학협력단 하지 절단 수술의 치료 반응성을 예측하는 방법
KR102517894B1 (ko) 2021-02-23 2023-04-04 연세대학교 산학협력단 당뇨발에 의한 하지 절단 수술의 치료 반응성을 예측하는 방법

Also Published As

Publication number Publication date
IL247837A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
US20220144969A1 (en) Methods for reducing cardiovascular risk
JP7467538B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
JP6994484B2 (ja) 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
JP6912374B2 (ja) 高コレステロール血症を有する高心血管リスク患者を処置するための方法
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP6616298B2 (ja) Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
CN106029096A (zh) 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
JP2019512472A (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
JP2020143156A (ja) 心血管リスクを低減させる方法
JP7104108B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
HK40114248A (en) Methods for reducing cardiovascular risk
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
HK1232890B (en) Methods for reducing cardiovascular risk
HK1232890A1 (en) Methods for reducing cardiovascular risk
JP2020037566A (ja) Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
HK1255470B (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220322